Apogee Therapeutics, Inc.APGENASDAQ

Loading chart...

Want to monitor APGE?

Get notified when price crosses targets, volume spikes, or RSI hits oversold

No description available.

Professional, Scientific, and Technical Services

Research and Development in Biotechnology (except Nanobiotechnology)

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance

Alerts

Key Statistics

About

News

A Rare Ground-Floor Entry in Hard-Rock Lithium: Elektros Inc. (OTC:ELEK) Positioned at a Bottom-Basement Valuation for Investors Seeking Early-Stage Upside

Coinbase Directors and CEO Facing Insider Trading Lawsuit

e.l.f. Beauty Stock Is Off to a Hot Start to 2026. Will It Continue?

Why Wall Street Is Betting Big on This Artificial Intelligence (AI) Infrastructure Stock

Why Microsoft Stock Dropped This Week

BTDR Deadline: BTDR Investors Have Opportunity to Lead Bitdeer Technologies Group Securities Fraud Lawsuit

Capstone Copper Resumes Operations at Mantoverde

BHP backs the next wave of exploration and technology talent in its biggest Xplor intake yet

OWL Deadline: OWL Investors Have Opportunity to Lead Blue Owl Capital Inc. Securities Fraud Lawsuit

The Sleeper Fintech Stock That Could Surge Before Wall Street Notices

A Bottom-Basement Lithium Entry Point for Investor Opportunity: Elektros Inc., a Lithium Mining Company, Advances Strategic Communications

Microsoft's historic plunge: Why the company lost $357 billion in value despite strong results

Forget Tech Stocks: The Telehealth Stock That's Riding the AI Wave Better Than Big Tech

Disney Earnings Need to Show Parks and Streaming Growth

SJS Investment Boosts Ultra-Short Treasury Position by $6.39 Million

Could This Artificial Intelligence (AI) Stock Double in 2026?

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN

Arons: "Extreme Growth" to Follow Rut, Top Picks in META, IBM & BA

NuScale Power Under $20: Your Last Chance to Buy?

Better Creative Tools Stock: Figma vs. Adobe